Browse by ▼

Nick Slepko

All Posts

  • The Joy of SEC

    By Nick Slepko - February 25, 2013 | Tickers: CYNO, UL

    Massachusetts-based BioChemics has developed a number of new drug delivery systems which allow treatments to be administered through the skin and which have the potential to revolutionize their big pharma partners or lay waste to big pharma's long term profits.  The company’s Founder, Chairman, President, and CEO John Masiz clears the air on some recent actions that the SEC has taken against the company.

    Nick Slepko: So, why more »

  • Carlos Slim Domit Talks Mexico & Beyond

    By Nick Slepko - February 25, 2013 | Tickers: AMX, AMOV, GPOVY, MSFT

    Carlos Slim Domit chair of Grupo Carso (NASDAQOTH: GPOVY) and co-chair of America Movil (NYSE: AMX)(NASDAQ: AMOV) talks about Mexico and beyond.

    [continued from Carlos Slim Domit Discusses the Era of Access]

    Slepko:  By decade’s end, where do you see Grupo Carso and America Movil?

    Slim Domit:  That’s always a difficult question, especially when trying to predict anything in the telecommunications industry.  I think our emphasis on more »

  • 9.1% of TB Drugs Fail Quality Control

    By Nick Slepko - February 25, 2013 | Tickers: CPHD, DSNKY, JNJ

    In the 1990s, New York spent over a billion dollars to battle an outbreak of tuberculosis, and now with almost one in ten doses of common anti-TB drugs failing to meet basic standards, there is growing concern that resistance may be making past treatments obsolete.  Two key anti-TB drugs, isoniazid and rifampicin, originally developed by Roche, have been shown in a study published this week in the International  Journal of more »

  • Carlos Slim Domit Discusses the Era of Access

    By Nick Slepko - February 25, 2013 | Tickers: AMX

    Carlos Slim Domit chair of Grupo Carso and co-chair of America Movil (NYSE: AMX)(NASDAQ AMOV) outs global developments in perspective.

    [continued from Carlos Slim Domit Shares Management Insights]

    Nick Slepko:  Your father is a great man.  Are you?  I ask because celebrity CEOs have become such an important part of investing for many in the US, but not so much in the rest of the world.  Moreover, Warren Buffett more »

  • Carlos Slim Domit Shares Management Insights

    By Nick Slepko - February 25, 2013 | Tickers: AMX, AMOV

    Carlos Slim Domit is the eldest son of Carlos Slim Helu and, now that his father has semi-retired to head up the family’s philanthropy, Slim Domit is the public face of one of the fastest growing business groups in world history.  In addition to chairing the Grupo Carso conglomerate since 1998, he also became co-chair of America Movil (NYSE: AMX)(NASDAQ: AMOV) in 2010, and is an active board more »

  • Russia from the Inside Out

    By Nick Slepko - February 23, 2013 | Tickers: GZPFY, OGZPY.PK, LSE, LUKOY.PK, SGTPY.PK

    Max Lutikov-Kurono was raised in Moscow, took his first job abroad in Morocco, got his MBA in Singapore while being the first graduate student from Russia at the NUS Business School. He later set up the first Russia-focused wealth management practice in Singapore. He is also a Director of Emerging Capital Group (a firm focusing on private equity investing in Asia's mining sector) and the Portfolio Manager of the more »

  • The Secrets to London’s Success

    By Nick Slepko - February 19, 2013 | Tickers: DLG, LSE, RVG, WAND

    Alastair Walmsley, Director of Equity Primary Markets at the London Stock Exchange Group (LSE: LSE) talks about the exchange and the wider group’s future prospects.

    [continued from Facebook is a New York Problem, Not a London One]

    Slepko:  What companies listed on your exchange have done particularly well recently?

    Walmsley:  Strong companies with a convincing story to tell will always shine, even in challenging global markets. This year has more »

  • The Apple of Pharmaceuticals

    By Nick Slepko - February 19, 2013 | Tickers: AAPL, GSK, JNJ, VRX

    Massachusetts-based BioChemics is a private pharmaceutical company that has developed a number of new drug delivery systems which allow treatments to be administered through the skin.  The company’s Founder, Chairman, President, and CEO John Masiz discusses the pharmaceutical and biotech industries. 

    [continued from How to Get a New-ish Drug to Market in 20% Less Time at 2% the Cost]

    Nick Slepko:  You have said that a broad based drug more »

  • Keys to Russian Investing: Oligarchs, Patriarchs, & Deep Purple

    By Nick Slepko - February 19, 2013 | Tickers: NILSY.PK, MAIL, RSHYY.PK, YNDX

    Max Lutikov-Kurono was raised in Moscow, took his first job abroad in Morocco, got his MBA in Singapore while being the first graduate student from Russia at the NUS Business School. He later set up the first Russia-focused wealth management practice in Singapore. He is also a Director of Emerging Capital Group (a firm focusing on private equity investing in Asia's mining sector) and the Portfolio Manager of the more »

  • Which Brazilian ETF?

    By Nick Slepko - February 19, 2013 | Tickers: EWZS, BRF, SCIF, IDXJ, RSXJ

    The Market Vectors Brazil Small-Cap ETF (NYSEMKT: BRF) was launched in May 2009 and as of 31 December 2012 had over 88% of the market share in the Brazil small-cap equity space. BRF was launched to tap the large domestic consumption element of the Brazilian economy.  Rafael Cordero heads the product management and product development of the International Equity ETF platform at Market Vectors. 

    [continued from The World Cup, the more »

  • Facebook is a New York Problem, Not a London One

    By Nick Slepko - February 19, 2013 | Tickers: FB, LSE, NDAQ, OTCM

    Alastair Walmsley, Director of Equity Primary Markets at the London Stock Exchange Group (LSE: LSE) talks about the exchange and the wider group’s future prospects. 

    Slepko:  Many have speculated that the disappointing and problematic Facebook (NASDAQ: FB) IPO hurt overall investor confidence in the US.  Has the Facebook fall out impacted your exchange as well?

    Walmsley:  Not really, Facebook was a one-off that impacted NASDAQ (NASDAQ: NDAQ) and the more »

  • Singapore Continues to Diversify Because It Must

    By Nick Slepko - February 19, 2013 | Tickers: DBSDY.PK, HUWHY.PK, S68, UOVEY.PK, WLMIY.PK

    The Singapore Exchange (SGX: S68) is Asia’s most internationalized exchange with more than 40% of its 777 listed companies originating outside of Singapore (and over half of its foreign listings coming from countries other than China).  The SGX is the world’s biggest offshore market for Asian equity futures, and are centered on Asia’s three largest economies – China, India, and Japan.  Nels Friets, the SGX’s Senior Vice more »

  • Kroll Ratings Take on US Banks, Europe Next

    By Nick Slepko - February 19, 2013 | Tickers: MHFI, MCO

    In only two years, Kroll Bond Rating Agency, in metric after metric, has been surpassing one credit ratings agency after another.  Founded by corporate intelligence legend Jules Kroll, the firm set out to “establish new standards for assessing risk and offering accurate, clear and transparent ratings,” and picked up where of Moody’s, (NYSE: MCO), S&P (NYSE: MHFI), and Fitch had seem to have given up.  Industry veteran Jim more »

  • How to Get a New-ish Drug to Market in 20% Less Time at 2% the Cost

    By Nick Slepko - February 19, 2013 | Tickers: BIIB, LLY, JNJ, MRK, NVS

    Massachusetts-based BioChemics is a private pharmaceutical company that has developed a number of new drug delivery systems which allow treatments to be administered through the skin.  The company’s Founder, Chairman, President, and CEO John Masiz discusses the pharmaceutical and biotech industries. 

    [continued from Smart Drugs: A New Hope]

    Nick Slepko:  According to the Wall Street Journal, seven million Americans spend over USD 25 billion every year on chronic wound more »

  • Russia: Beyond Oil

    By Nick Slepko - February 19, 2013 | Tickers: MT, MTL, MBT, TELNY.PK, VIP

    Max Lutikov-Kurono was raised in Moscow, took his first job abroad in Morocco, got his MBA in Singapore while being the first graduate student from Russia at the NUS Business School. He later set up the first Russia-focused wealth management practice in Singapore. He is also a Director of Emerging Capital Group (a firm focusing on private equity investing in Asia's mining sector) and the Portfolio Manager of the more »

  • The World Cup, the Olympics, & Brazil

    By Nick Slepko - February 19, 2013 | Tickers: EQUEY, GOL, IOCJY.PK, LLXLY.PK, BRF

    The Market Vectors Brazil Small-Cap ETF (NYSEMKT: BRF) was launched in May 2009 and as of 31 December 2012 had over 88% of the market share in the Brazil small-cap equity space. BRF was launched to tap the large domestic consumption element of the Brazilian economy.  Rafael Cordero heads the product management and product development of the International Equity ETF platform at Market Vectors. 

    [continued from Market Vectors Talks Brazil more »

  • A Singapore for Every Occasion

    By Nick Slepko - February 19, 2013 | Tickers: BIDU, CMGE, ASEA, LSE, EMG, S68

    The Singapore Exchange (SGX: S68) is Asia’s most internationalized exchange with more than 40% of its 777 listed companies originating outside of Singapore (and over half of its foreign listings coming from countries other than China).  The SGX is the world’s biggest offshore market for Asian equity futures, and are centered on Asia’s three largest economies – China, India, and Japan.  Nels Friets, the SGX’s Senior Vice more »

  • Kroll Credit Ratings: Old School Values, Modern Methods, New Paradigms

    By Nick Slepko - February 19, 2013 | Tickers: C, MHFI, MCO, MORN

    In only two years, Kroll Bond Rating Agency, in metric after metric, has been surpassing one credit ratings agency after another.  Founded by corporate intelligence legend Jules Kroll, the firm set out to “establish new standards for assessing risk and offering accurate, clear and transparent ratings,” and picked up where of Moody’s, (NYSE: MCO), S&P (NYSE: MHFI), and Fitch had seem to have given up.  Industry veteran Jim more »

  • Banking, Beer, & BP

    By Nick Slepko - February 19, 2013 | Tickers: BKVZY, BP, GS, HEINY, SBRCY.PK

    Max Lutikov-Kurono was raised in Moscow, took his first job abroad in Morocco, got his MBA in Singapore while being the first graduate student from Russia at the NUS Business School. He later set up the first Russia-focused wealth management practice in Singapore. He is also a Director of Emerging Capital Group (a firm focusing on private equity investing in Asia's mining sector) and the Portfolio Manager of the more »

  • Market Vectors Talks Brazil

    By Nick Slepko - February 19, 2013 | Tickers: COLUF, MFRSY, BRF, MMXMY.PK

    The Market Vectors Brazil Small-Cap ETF (NYSEMKT: BRF) was launched in May 2009 and as of 31 December 2012 had over 88% of the market share in the Brazil small-cap equity space. BRF was launched to tap the large domestic consumption element of the Brazilian economy.  Rafael Cordero heads the product management and product development of the International Equity ETF platform at Market Vectors. 

    Nick Slepko: Brazil?

    Rafael Cordero:  Brazil more »

  • Page 1 of 10